Ovarian Cancer Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) – Estimates DelveInsight | AstraZeneca, Genentech, Genmab, Daiichi Sankyo, Aravive, Gradalis, Merck

Ovarian Cancer Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) -  Estimates DelveInsight | AstraZeneca, Genentech, Genmab, Daiichi Sankyo, Aravive, Gradalis, Merck
Delveinsight Business Research LLP
As per DelveInsight, the Ovarian Cancer Market is anticipated to evolve immensely in the coming years owing to the increase in diagnosed cases, rising awareness about the disease, increased R&D for developing new molecules, and expected commercial success of upcoming therapies in the 7MM.

DelveInsight’s “Ovarian Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Ovarian Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Ovarian Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Ovarian Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Ovarian Cancer: An Overview

Cancer is a generic term in which abnormal cells in the body grow out of control. Cells in nearly any part of the body can become cancerous and spread. However, it is typically named for the part of the body where it starts, even if it spreads to other body parts later.

According to the Centers for Disease Control and Prevention, Ovarian Cancer is a group of diseases that originates in the ovaries or the related areas of the fallopian tubes and the peritoneum. It accounts for only 3% of cancers in women. Ovarian Cancer can be malignant or cancerous, cells that affect tissues in the ovaries.

Ovarian Cancer is now known to be several distinct diseases named after the type of cell they come from epithelial, germ cell, and stromal. Epithelial Ovarian Cancer is the most common type of Ovarian Cancer. They start from the cells that cover the outer surface of the ovary, whereas germ cell tumors start from the cells that produce the ova, and stromal tumors start from structural tissue cells that hold the ovary together and produce the female hormones estrogen and progesterone. These types are further classified into various subtypes.

There is no single test to diagnose Ovarian Cancer; instead, the physicians consider the symptoms together with the results of patient history, physical examination, biopsies, blood tests, and imaging scans (ultrasound, CT, and MRI).

Currently, there are several types of medications used for treatment purposes, namely PARP inhibitors, immunomodulators, anti-angiogenic agents, platinum-containing compounds, and others. At times, combination therapy and dietary supplementation are also prescribed.

Ovarian Cancer Market Key Facts

  • According to DelveInsight’s estimate, the total diagnosed incident cases of Ovarian Cancer in the 7MM comprised 58,366 cases in 2022 and are projected to reach up to 46,086 cases by 2032. These cases are anticipated to decrease during the study period.

  • According to DelveInsight’s estimates, in EU4 and the UK, the highest number of total diagnosed incident cases of Ovarian Cancer was observed in Germany, with 6,637 cases in 2022 which is estimated to decrease and reach 5,077 cases by 2032.

  • According to the Centers for Disease Control and Prevention (CDC) (2022), ovarian cancer is a group of diseases that originates in the ovaries or the related areas of the fallopian tubes and the peritoneum; it accounts for only 3% of cancers in women. 

Ovarian Cancer Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Ovarian Cancer pipeline therapies. It also thoroughly assesses the Ovarian Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Ovarian Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Ovarian Cancer Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Ovarian Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Ovarian Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Ovarian Cancer Epidemiology, Segmented as –

  • Total Incident Cases of Ovarian Cancer

  • Type-specific Incident Cases of Ovarian Cancer

  • Subtype-specific Incident Cases of Epithelial Ovarian Cancer

  • Age-specific Incident Cases of Ovarian Cancer

  • Total treated Cases of Ovarian Cancer

Ovarian Cancer Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Ovarian Cancer market or expected to be launched during the study period. The analysis covers the Ovarian Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Ovarian Cancer drugs based on their sale and market share.

The report also covers the Ovarian Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Ovarian Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Ovarian Cancer Market Will Evolve and Grow by 2032 @ 


Ovarian Cancer Therapeutics Analysis

Currently, the most active therapeutic agents against newly diagnosed Ovarian Cancer are platinum analogs i.e., cisplatin or carboplatin, with the addition of a taxane i.e., either paclitaxel or docetaxel. Treatment for first-line newly diagnosed Ovarian Cancer includes either primary surgical cytoreduction (to debulk tumors) followed by the combination platinum-based chemotherapy or the administration of chemotherapy before surgery (neoadjuvant therapy) followed by interval surgical cytoreduction and additional chemotherapy after surgery.

Women diagnosed with advanced-stage Ovarian Cancer have to go through a common problem of recurrence after the initial platinum-based chemotherapy, and also most patients have shown resistance to platinum-based chemotherapy. However, recent advances in new therapeutics for recurrent Ovarian Cancer treatment have shown to have encouraging results. The new treatment methods include angiogenesis inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors, and immunotherapeutic agents.

Still, there is a high unmet need with the current therapies and well-defined screening programs for Ovarian Cancer. Ovarian Cancer generally goes undiagnosed until it gets into the advanced stages, where the disease then gets very aggressive and easily progresses into other deadly stages.

In the continuous pursuit of enhancing treatment options, several major pharma and biotech companies are actively involved in developing therapies for Ovarian Cancer. Among these, Genentech stands out as a leading player with Ovarian Cancer drug candidates advancing to the most advanced stage, Phase III clinical trials. 

Ovarian Cancer Companies Actively Working in the Therapeutics Market Include

Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (Canaria Bio), Alkermes, Hoffman-La Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, Genmab, On Target Laboratories, Chipscreen Biosciences, Aprea Therapeutics, Ellipses Pharma, Impact Therapeutics, BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and many others. 

Emerging and Marketed Ovarian Cancer Therapies Covered in the Report Include:

  • LYNPARZA (olaparib): AstraZeneca and MSD’s

  • Atezolizumab: Genentech

  • Tisotumab Vedotin: Genmab

  • SON-1010: Sonnet Biotherapeutics

  • DS-6000a: Daiichi Sankyo Company

  • Stenoparib (2X-121): Allarity Therapeutics

  • Adavosertib (AZD-1775): AstraZeneca

  • Tedopi (OSE 2101): OSE Immunotherapeutic

  • CriPec (CPC634): Cristal Therapeutics

  • OPDIVO (nivolumab): Bristol-Myers Squibb/Ono Pharmaceuticals

  • KEYTRUDA (pembrolizumab): Merck 

  • Batiraxcept (AVB-500): Aravive Biologics

  • Upifitamab Rilsodotin (XMT-1536): Mersana Therapeutics

  • RUBRACA (rucaparib): Clovis Oncology

  • Vigil: Gradalis

  • Avutometinib (VS-6766): Verastem Oncology

  • Ofra-vec (ofranergene obadenovec; VB-111): VBL Therapeutics

  • Veliparib (ABT-888): AbbVie

  • Seribantumab: Elevation oncology

  • IMFINZI (durvalumab): AstraZeneca

  • Oregovomab: OncoQuest Pharmaceuticals (CanariaBio)

  • Nemvaleukin alfa: Alkermes

  • ROZLYTREK (entrectinib): Hoffman-la Roche

  • Maveropepimut-S (DPX-Survivac): IMV

  • ZEJULA (niraparib): GlaxoSmithKline

  • Relacorilant (CORT125134): Corcept Therapeutics

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Ovarian Cancer Competitive Intelligence Analysis

4. Ovarian Cancer Market Overview at a Glance

5. Ovarian Cancer Disease Background and Overview

6. Ovarian Cancer Patient Journey

7. Ovarian Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Ovarian Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Ovarian Cancer Unmet Needs

10. Key Endpoints of Ovarian Cancer Treatment

11. Ovarian Cancer Marketed Therapies

12. Ovarian Cancer Emerging Drugs and Latest Therapeutic Advances

13. Ovarian Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Ovarian Cancer Market Outlook (In US, EU5, and Japan)

16. Ovarian Cancer Companies Active in the Market

17. Ovarian Cancer Access and Reimbursement Overview

18. KOL Views on the Ovarian Cancer Market

19. Ovarian Cancer Market Drivers

20. Ovarian Cancer Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Tuberous Sclerosis Complex Market

“Tuberous Sclerosis Complex Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Tuberous Sclerosis Complex market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Tuberous Sclerosis Complex market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices